Home > Dermatology > AAD 2018 > Psoriasis: an update > Oral therapeutics, supersaturation and excimer laser

Oral therapeutics, supersaturation and excimer laser

Presented By
Dr John Koo (University of California San Francisco), Phototherapy and Skin Treatment Clinic
Conference
AAD 2018
Trial
ESTEEM 2

Dr John Koo, of the Phototherapy and Skin Treatment Clinic at the University of California San Francisco, gave an update on new data on oral therapeutics in psoriasis [1].

Apremilast appears to have lower efficacy than some biologic agents. However, its ease of administration as an oral agent, coupled with a mild side-effect profile, make it an attractive option for many psoriasis patients.

A poster presented at the annual meeting of the European Academy of Dermatology and Veneorology (EADV) in Geneva provided more insight into the mode of action of this small molecule: it assessed the influence of apremilast on different cytokines compared to placebo [2].

Data came from the ESTEEM 2 trial, which confirmed the therapeutic concept that apremilast works as a cytokine modulator. It has a distinct effect on the proinflammatory cytokines IL-17A, IL-17F and IL-22, but lowers TNF-α to only a minimal amount. “I think it is therefore a good idea to combine apremilast ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on